A genre of injectable medications, GLP-1 drugs harness the capability to regulate blood sugar levels by enhancing insulin secretion and suppressing glucagon production, thereby mitigating hyperglycaemia
doi: 10.1016/S1474-4422(20)30231-3 [DOI] [PMC free article] [PubMed] [Google Scholar] 11
Prior studies with the injectable form established cardiovascular benefit, but oral semaglutide had previously demonstrated only cardiovascular safety
Your health journey is unique, and having the right information helps you and your healthcare team make the best possible decisions for your long-term wellness
Learn more at #GLP1 #Sustainability #medicaldevice #healthcareinnovation E3D Elcam Drug Delivery Devices Post The GLP-1 (Glucagon-Like Peptide-1) drug market is rapidly expanding, projected to grow from $16.53 billion in 2021 to $126 billion by 2029 (link below)
Key protocol components, including eligibility criteria, treatment strategies, assignment procedures, follow-up, outcome definitions, causal contrast, identifying assumptions and the data analysis plan, were translated into operational definitions using validated claims-based algorithms and observational analogs of key study design choices
